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Abstract: Recent advances in the management of patients with haematological malignancies and 
transplant  recipients  have  paralleled  an  increase  in  the  incidence  of  fungal  diseases  due  to 
pathogenic  genera  such  as  Candida
including  Fusarium and  Zygomycetes
opportunistic infections have high mortality. Rapid and reliable species identification is essential 
for  antifungal  treatment,  but  detection  of  the  increasing
conventional  phenotypic  methods  remains  difficult  and  time
sometimes be inconclusive, especially for unusual species. New diagnostic techniques (e.g., 1,3
d-glucan detection) could improve this scenario, although further studies are necessary to confirm 
their usefulness in clinical practice.
Introduction: Despite  the  development  of  new 
techniques  and  new  antifungal  agents,  diagnosis  of 
invasive fungal infection (IFI), which still relies upon a 
combination  of  clinical  observation  and  laboratory 
investigation,  remains  a  challenge  especially  for 
immunocompromised  patients  with  haematological 
disease.
1  This  has  important  clinical  repercussions 
since  delayed  diagnosis  and  therapy  contribute 
significantly to the high mortality rates associated with 
IFIs,
2 whereas early intervention with antifungal drugs 
may result in more effective management of high
patients.
3 While  superficial  and  subcutaneous  fungal 
infections  often  produce  characteristic  lesions  that 
suggest  the  diagnosis,  a  thorough  knowledge  of 
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MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
www.mjhid.org ISSN 2035-3006
he Laboratory Diagnosis of Invasive Fungal Infections.
, Elena De Carolis
1, Patrizia Posteraro
2 and Maurizio Sanguinetti
Institute of Microbiology, Università Cattolica del Sacro Cuore, Largo F. Vito, 1-00168, Rome, Italy.
nical Pathology and Microbiology, Ospedale San Carlo-IDI IRCSS, via 
Maurizio Sanguinetti, Institute of Microbiology, Università Cattolica del Sacro Cuore. 
4964, Fax: +39-06-3015-152. E-mail: msanguinetti@rm.unicatt.it
have declared that no competing interests exist.
e2011002, DOI 10.4084/MJHID.2011.002
http://www.mjhid.org/article/view/7438
This  is  an  Open  Access  article  distributed  under  the  terms  of  the  Creative  Commons  Attribution  License
http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, 
the original work is properly cited.
Recent advances in the management of patients with haematological malignancies and 
transplant  recipients  have  paralleled  an  increase  in  the  incidence  of  fungal  diseases  due  to 
Candida and  Aspergillus and  the  emergence of  less  comm
Zygomycetes.  Despite  availability  of  new  antifungal  agents  these 
opportunistic infections have high mortality. Rapid and reliable species identification is essential 
for  antifungal  treatment,  but  detection  of  the  increasing diversity  of  fungal  pathogens  by 
conventional  phenotypic  methods  remains  difficult  and  time-consuming,  and  the  results  may 
sometimes be inconclusive, especially for unusual species. New diagnostic techniques (e.g., 1,3
ve this scenario, although further studies are necessary to confirm 
their usefulness in clinical practice.
Despite  the  development  of  new 
techniques  and  new  antifungal  agents,  diagnosis  of 
invasive fungal infection (IFI), which still relies upon a 
combination  of  clinical  observation  and  laboratory 
investigation,  remains  a  challenge  especially  for 
sed  patients  with  haematological 
This  has  important  clinical  repercussions 
since  delayed  diagnosis  and  therapy  contribute 
significantly to the high mortality rates associated with 
whereas early intervention with antifungal drugs 
in more effective management of high-risk 
While  superficial  and  subcutaneous  fungal 
infections  often  produce  characteristic  lesions  that 
suggest  the  diagnosis,  a  thorough  knowledge  of 
potential causative organisms is yet required to aid the 
diagnostic process, mainly in situations where systemic 
fungal  infection  is  suspected  but  the  clinical 
presentation  is  nonspecific  and  then  ascribable  to  a 
wide  range  of  infections,  underlying  illnesses,  or 
complication of treatments.
4
The exact identification of the infecting organism is 
became  essential  in  light  of  the  increased  use  of 
prophylactic schedules that predispose the patient not 
just  to  fungal  infection,  but  also  to  the  selection  of 
fungal species such as non-
glabrata and  C.  krusei
Scedosporium species,  and 
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Recent advances in the management of patients with haematological malignancies and 
transplant  recipients  have  paralleled  an  increase  in  the  incidence  of  fungal  diseases  due  to 
and  the  emergence of  less  common  genera 
.  Despite  availability  of  new  antifungal  agents  these 
opportunistic infections have high mortality. Rapid and reliable species identification is essential 
diversity  of  fungal  pathogens  by 
consuming,  and  the  results  may 
sometimes be inconclusive, especially for unusual species. New diagnostic techniques (e.g., 1,3-beta-
ve this scenario, although further studies are necessary to confirm 
potential causative organisms is yet required to aid the 
gnostic process, mainly in situations where systemic 
fungal  infection  is  suspected  but  the  clinical 
presentation  is  nonspecific  and  then  ascribable  to  a 
wide  range  of  infections,  underlying  illnesses,  or 
4
n of the infecting organism is 
became  essential  in  light  of  the  increased  use  of 
prophylactic schedules that predispose the patient not 
just  to  fungal  infection,  but  also  to  the  selection  of 
-albicans Candida (e.g., C. 
C.  krusei),  Aspergillus terreus, 
species,  and  Zygomycetes,  many  of Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
which  are  intrinsically  resistant  to  the  available 
antifungal agents.
5,6
Culture-based  detection  methods:  Laboratory 
diagnosis  of  IFI  remains  based  on  conventional 
approaches,  such  as  the  direct  microscopically 
detection  of  the  etiologic  agent  in  clinical  specimen 
and the isolation and identification of the pathogen in 
culture,  and  non-culture  based  methods  involving 
detection  of a  serologic response to  the  pathogen or 
other marker of its presence such as fungal antigens or 
metabolites.
4 Visual  examination  of  fungi  in  tissue 
samples  allows  presumptive  identification  based  on 
cellular  morphology  and  staining  properties,  but  it 
should  be  appreciated  that  invasive  procedures 
necessary  to  obtain  biopsies  may  be  precluded  in 
haematological  patients.  It  should  be  noted  that 
microbiological  cultures  are  often  insensitive  or  of 
limited  use,  since  even  with  modern  blood  cultures 
systems candidaemia can be transient and not detected, 
or  Aspergillus cannot  be  cultured  from  a  significant 
proportion  of  sputum  or  bronchoalveolar  lavage 
samples from patients with invasive aspergillosis (IA).
7
Although a variety of culture media and incubation 
conditions  may  be  required  for  recovery  of  fungal 
agents,  chromogenic  primary  isolation  media  (e.g., 
CHROMagar Candida medium) can be employed for 
the  presumptive  identification  of  the  most  medically 
important Candida species, including C. albicans, C. 
tropicalis,  C.  glabrata,  and  C.  parapsilosis.  Most 
yeasts isolated from clinical samples can be identified 
using one of the numerous commercial identification 
systems, such as API 20C AUX, VITEK 2, and RapID 
Yeast Plus.
4,8 Although the kits are relatively easy to 
use,  it  should  be  remembered  that  additional 
morphologic-based  tests  are  often  required  to  avoid 
confusion  between  organisms  with  identical 
biochemical profiles. 
Unlike pathogenic yeasts, filamentous fungi can be 
identified  only  by  visualization  of  macroscopic 
(colonial  form,  surface  colour,  and  pigmentation)  or 
microscopic  (spore-bearing  structures)  morphologic 
characteristics, following to sub-cultivation of a mould 
isolate to encourage sporulation,
4 a process that takes 
days to weeks. In addition to the use of genetic probes 
for  the  culture  confirmation  of  dimorphic  systemic 
fungal  pathogens  (e.g.,  Histoplasma capsulatum),  an 
alternative  and  useful  approach  to  the  detection  and 
identification of fungi in clinical specimens involves a 
broad-range polymerase chain reaction (PCR) followed 
by  nucleic acid  sequencing,  after  which  the  nucleic 
acid  sequence  is  compared  with  known  sequence 
database  and  identification  is  based  on  DNA 
homology.
9 However, these methods are expensive and 
time-consuming, and they are not currently suitable for 
routine identification.
By  contrast,  matrix-assisted  laser-
desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF MS) is becoming a reliable method for 
identification  of  microorganisms.  The  remarkable 
reproducibility  of  the  methodology  is  based  on  the 
measurement  of  constantly  expressed  and  highly 
abundant  proteins  such  as  ribosomal  molecules.
10,11 
Some recent studies have shown the potential of the 
MALDI-TOF  technique  to  identify  fungal  clinical 
species  such  as  Aspergillus and  Fusarium.  Recently, 
the  MALDI-TOF  technology  provided  a  fast  and 
accurate identification of common and unusual species 
of  Aspergillus when  tested  on  124  clinical  and  16 
environmental  isolates.
12 With  regard  to  Fusarium
species, a recent case report supported the usefulness 
of  MALDI-TOF  analysis  in  diagnosing  an  infection 
due  to  Fusarium  proliferatum,  which  is  a  very 
infrequent pathogen within this genus.
13
Antigen-based detection methods: To facilitate early 
diagnosis of IFI, important advances have been made 
in  the  development  of  laboratory  markers  (e.g., 
galactomannan  [GM]  and  1,3-beta-d-glucan  [BG] 
assays),  which  have  led  to  the  potential  for  newer 
paradigms regarding prevention and early treatment of 
IFIs.
14 Among fungal  markers,  GM, a component of 
fungal cell wall that can be detected by a sandwich-
type enzyme-linked immunosorbent assay (ELISA) in 
serum  or  plasma,
15 bronchoalveolar  lavage  (BAL) 
fluid,
16,17  and cerebrospinal  fluid,
18 has recently been 
approved by the US Food and Drug Administration at a 
serum cut-off of 0.5, as a diagnostic adjunct for IA.
14
Together  with  clinical  criteria,  a  positive  serum  or 
BAL fluid GM would strongly suggest probable IA, as 
defined by authoritative consensus criteria.
19 However, 
this technique has shown contradictory results, in terms 
of  sensitivity  and  specificity,  due  to  several  factors, 
including the impact of prior antifungal therapy on the 
levels  of  circulating  fungal  components,
20 the 
occurrence of false-positive results in association with 
some  antibiotic  treatments,
21,22  and  the  different  cut-
offs  of  positivity  among  studies.
14 Thus,  a  recently 
published  meta-analysis  of  27  studies  showed  an 
overall sensitivity of 71% and specificity of 89% for 
proven  cases  of  IA  when  used  for  surveillance.
23 In 
addition, GM also correlates well with outcome.
24
In contrast to GM, BG is a cell wall constituent of 
several  fungi,  including  Aspergillus,  Candida,  and 
Fusarium, a spectrum of pathogens that encompasses 
the majority of those emerging in neutropenic patients 
with  either  prolonged  neutropenia  or  chemotherapy-
induced mucositis, with some notable exceptions such 
as Zygomycetes, a rare but emerging cause of invasive Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
mycosis.
25,26 Measurement  of  serum  BG  has  been 
shown to be an aid in the diagnosis of fungaemia and 
deep-seated  mycoses,  including  IA.
27,28 Among 
commercially available assays, the Fungitell, which is 
also  an  ELISA  technique,  is  widely  used  to  detect 
serum BG concentrations as low as 1 pg/mL.
27 The cut-
off  for  a  positive  result  is >80  pg/ml.  As  with  GM, 
variable results have been reported for BG assay, with 
a  slightly  higher  sensitivity  and  specificity,  ranging 
from 70% to 90%.
28,29 When performances of both GM 
and  BD  tests  were  compared  to  determine  their 
diagnostic  usefulness  for  high-risk  haematological 
malignancy patients, GM assay was significantly better 
for  detecting  non-fumigatus Aspergillus species, 
whereas BG was shown to have a higher sensitivity in 
detecting IA and other mould infections.
30
Non-culture  based  methods  for  diagnosis  of 
candidiasis are of limited value because the levels of 
circulating antigens are low and the transient nature of 
the antigenaemia requires sensitive assays and frequent 
sampling  of  at-risk  patients.
1,31 However,  the  use  of 
Platelia  Candida,  an  ELISA  that  combines  the 
detection  of  mannan  antigen  and  anti-mannan 
antibodies in serum, led to earlier diagnosis of Candida
infection  when  compared  with  blood  cultures.
31 In 
haematological  patients  with  hepatosplenic  lesions, 
assessing  mannan/anti-mannan  antibodies  shortened 
significantly  the  median  time  of  diagnosis  of 
candidiasis when compared with imaging.
32
Molecular-based  detection  methods:  A  range  of 
polymerase chain reaction (PCR)-based methods have 
been  developed  with  the  prospect  of  give  highly 
specific, highly sensitive, and rapid means for fungal 
detection  and  identification.
33 Most  of  them  have 
focused  on  Aspergillus and  Candida species,  using 
different specimens types (e.g., serum, plasma, or BAL 
fluid),  even  though  pan-fungal  PCR  amplification 
technology  may  be  able  to  detect  a  broad  range  of 
fungal  targets.
33 Although PCR has  been  studied for 
years,  the  lack  of  standardization  and  clinical 
validation  has  led  to  its  exclusion  from  consensus 
criteria  for  defining  IFI.
19 Nevertheless,  a  recent 
prospective evaluation of serial PCR assays against
34 or 
along  with  GM  and  computed  tomography
35 was 
carried  out  in  haematological  patients,  thus  showing 
acceptable  sensitivity  and  specificity.  In  such  one 
study, the combination of serial PCR and GM detected 
100% of aspergillosis cases, with a positive predictive 
value of 75.1%.
35 Of note, in a systematic review and 
meta-analysis of Aspergillus PCR tests for diagnosis of 
IA,
36 the authors proposed that a single PCR-negative 
test  is  sufficient  to  exclude  IA,  whereas  two  PCR-
positive  results  are  required  to  confirm  disease. 
Compared with Aspergillus PCR, only a few Candida
PCR  methods  have  received  major  clinical 
evaluation.
37 As  confirmed  by  a  national  consensus 
evaluation,
38 performance  of  these  tests  is  generally 
good,  with  sensitivities  and  specificities  consistently 
>90%.
33 Although addressed to critically ill patients, a 
prospective  clinical  trial  published  in  2008  reported 
positive  predictive  values  and  negative  predictive 
values of >90% for a PCR method that detects several 
species of Candida.
39
Conclusion: Molecular detection  methods,  combined 
with  additional  microbiological  and  clinical 
information,  has  the  potential  not  only  to  accurately 
and  rapidly identify  fungal  pathogens,  but  also  to 
indicate whether the pathogen is likely to respond to 
conventional antifungal treatment.
9 Inclusion of these 
methods  in  a  diagnostic  surveillance  strategy  to 
exclude IFI in high-risk patients with haematological 
malignancy
40 should  result  in  improved  clinical 
management,  thus  allowing  more  rational  use  of 
antifungal drugs.
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